62 related articles for article (PubMed ID: 12839929)
1. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells.
Fausch SC; Da Silva DM; Kast WM
Cancer Res; 2003 Jul; 63(13):3478-82. PubMed ID: 12839929
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis.
Jain M; Yadav D; Jarouliya U; Chavda V; Yadav AK; Chaurasia B; Song M
Pathogens; 2023 Nov; 12(12):. PubMed ID: 38133265
[TBL] [Abstract][Full Text] [Related]
3. Unraveling Immunological Dynamics: HPV Infection in Women-Insights from Pregnancy.
Condrat CE; Cretoiu D; Radoi VE; Mihele DM; Tovaru M; Bordea CI; Voinea SC; Suciu N
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896788
[TBL] [Abstract][Full Text] [Related]
4. The association of cervicovaginal Langerhans cells with clearance of human papillomavirus.
Dai W; Gui L; Du H; Li S; Wu R
Front Immunol; 2022; 13():918190. PubMed ID: 36311788
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus and cervical cancer: an insight highlighting pathogenesis and targeting strategies.
Ojha PS; Maste MM; Tubachi S; Patil VS
Virusdisease; 2022 Jun; 33(2):132-154. PubMed ID: 35991700
[TBL] [Abstract][Full Text] [Related]
6. A Comparative Study on Delivery of Externally Attached DNA by Papillomavirus VLPs and Pseudoviruses.
Brendle S; Cladel N; Balogh K; Alam S; Christensen N; Meyers C; Hu J
Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960247
[TBL] [Abstract][Full Text] [Related]
7. Peptide-based supramolecular vaccine systems.
O'Neill CL; Shrimali PC; Clapacs ZE; Files MA; Rudra JS
Acta Biomater; 2021 Oct; 133():153-167. PubMed ID: 34010691
[TBL] [Abstract][Full Text] [Related]
8. Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.
Valencia SM; Zacharia A; Marin A; Matthews RL; Wu CK; Myers B; Sanders C; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Andrianov AK; Marshall JD
Hum Vaccin Immunother; 2021 Aug; 17(8):2748-2761. PubMed ID: 33573433
[TBL] [Abstract][Full Text] [Related]
9. The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.
Janitzek CM; Carlsen PHR; Thrane S; Khanna VM; Jakob V; Barnier-Quer C; Collin N; Theander TG; Salanti A; Nielsen MA; Sander AF
Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33562114
[TBL] [Abstract][Full Text] [Related]
10. Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.
Zepeda-Cervantes J; Ramírez-Jarquín JO; Vaca L
Front Immunol; 2020; 11():1100. PubMed ID: 32582186
[TBL] [Abstract][Full Text] [Related]
11. Virus-like particle vaccines: immunology and formulation for clinical translation.
Donaldson B; Lateef Z; Walker GF; Young SL; Ward VK
Expert Rev Vaccines; 2018 Sep; 17(9):833-849. PubMed ID: 30173619
[TBL] [Abstract][Full Text] [Related]
12. Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation.
Taylor JR; Fernandez DJ; Thornton SM; Skeate JG; Lühen KP; Da Silva DM; Langen R; Kast WM
Sci Rep; 2018 Aug; 8(1):11642. PubMed ID: 30076379
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and challenges for human papillomavirus vaccination in cancer.
Roden RBS; Stern PL
Nat Rev Cancer; 2018 Apr; 18(4):240-254. PubMed ID: 29497146
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Rift Valley Fever Vaccine Development.
Faburay B; LaBeaud AD; McVey DS; Wilson WC; Richt JA
Vaccines (Basel); 2017 Sep; 5(3):. PubMed ID: 28925970
[TBL] [Abstract][Full Text] [Related]
15. Evasion of host immune defenses by human papillomavirus.
Westrich JA; Warren CJ; Pyeon D
Virus Res; 2017 Mar; 231():21-33. PubMed ID: 27890631
[TBL] [Abstract][Full Text] [Related]
16. The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis.
Wüstenhagen E; Hampe L; Boukhallouk F; Schneider MA; Spoden GA; Negwer I; Koynov K; Kast WM; Florin L
J Virol; 2016 Dec; 90(23):10629-10641. PubMed ID: 27654294
[TBL] [Abstract][Full Text] [Related]
17. The CD63-Syntenin-1 Complex Controls Post-Endocytic Trafficking of Oncogenic Human Papillomaviruses.
Gräßel L; Fast LA; Scheffer KD; Boukhallouk F; Spoden GA; Tenzer S; Boller K; Bago R; Rajesh S; Overduin M; Berditchevski F; Florin L
Sci Rep; 2016 Aug; 6():32337. PubMed ID: 27578500
[TBL] [Abstract][Full Text] [Related]
18. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation.
Woodham AW; Yan L; Skeate JG; van der Veen D; Brand HH; Wong MK; Da Silva DM; Kast WM
Papillomavirus Res; 2016 Dec; 2():21-30. PubMed ID: 27182559
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
Da Silva DM; Woodham AW; Naylor PH; Egan JE; Berinstein NL; Kast WM
J Interferon Cytokine Res; 2016 May; 36(5):291-301. PubMed ID: 26653678
[TBL] [Abstract][Full Text] [Related]
20. Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.
Shirbaghaee Z; Bolhassani A
Biopolymers; 2016 Mar; 105(3):113-32. PubMed ID: 26509554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
